395 related articles for article (PubMed ID: 31699671)
21. Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients.
Liu L; Liu Z; Qu S; Zheng Z; Liu Y; Xie X; Song F
Diagn Pathol; 2013 May; 8():71. PubMed ID: 23635316
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.
Kuroi K; Toi M; Ohno S; Nakamura S; Iwata H; Masuda N; Sato N; Tsuda H; Kurosumi M; Akiyama F
Breast Cancer; 2015 Sep; 22(5):486-95. PubMed ID: 24338638
[TBL] [Abstract][Full Text] [Related]
23. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
24. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes.
Kim HM; Koo JS
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580398
[TBL] [Abstract][Full Text] [Related]
27. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
29. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
30. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
31. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.
Zhao CL; Singh K; Brodsky AS; Lu S; Graves TA; Fenton MA; Yang D; Sturtevant A; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1036. PubMed ID: 31675929
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
33. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
34. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
37. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
[TBL] [Abstract][Full Text] [Related]
38. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Specht K; Harbeck N; Smida J; Annecke K; Reich U; Naehrig J; Langer R; Mages J; Busch R; Kruse E; Klein-Hitpass L; Schmitt M; Kiechle M; Hoefler H
Breast Cancer Res Treat; 2009 Nov; 118(1):45-56. PubMed ID: 18925433
[TBL] [Abstract][Full Text] [Related]
39. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.
Tsang JY; Ho CS; Ni YB; Shao Y; Poon IK; Chan SK; Cheung SY; Shea KH; Marabi M; Tse GM
Cancer Immunol Immunother; 2020 May; 69(5):799-811. PubMed ID: 32055918
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]